Latest Dilution News

Fat Prophets Global Contrarian Fund Ltd announces a special fully franked dividend of AUD 0.05 per share, coupled with a dividend reinvestment plan offering a 2.5% discount. Key dates for investors are set for late August and September 2025.

Fat Prophets Global Contrarian Fund has announced a fully franked special dividend of 5 cents per share, reflecting strong investment performance. The dividend reinvestment plan offers shareholders a 2.5% discount on reinvested shares, signaling confidence in future growth.

Astute Metals NL sharpens its focus on Nevada’s rich mineral landscape, unveiling fresh high-grade gold targets at Needles and reaffirming lithium potential at Red Mountain amid leadership changes.

Pengana International Equities Limited has announced a fully franked ordinary dividend of AUD 0.0135 per share for the quarter ending June 2025, with a Dividend Reinvestment Plan available to shareholders.

Lake Resources has raised $2.1 million through its At-the-Market facility by issuing 65 million shares to Acuity Capital, while extending the agreement to 2031 to support its Kachi Project and working capital needs.

Emmerson Resources’ latest Scoping Study confirms the White Devil Gold Project as a Major Mine, projecting robust financial returns and a seven-year mine life. With feasibility studies underway and a strategic JV structure, the project is poised for development in the Northern Territory.

Macarthur Minerals has updated its rights issue prospectus, introducing a cap on the underwriter's shareholding and revising key offer terms. These changes aim to balance funding needs with shareholder control and regulatory compliance.

Argenica Therapeutics has dosed the final patient in its Phase 2 trial for ARG-007 in acute ischaemic stroke, with topline results expected in Q3 2025. Meanwhile, the FDA has placed a clinical hold on its US trial application, introducing uncertainty for US development.

Nyrada Inc. is set to launch a Phase IIa clinical trial of Xolatryp™, aiming to reduce heart muscle damage in acute myocardial infarction patients undergoing PCI. The trial, planned for early 2026, follows promising Phase I safety results and strong preclinical cardioprotection data.

Inhalerx Limited has drawn $247,000 from a $38.5 million funding facility to advance clinical trials for its IRX-211 and IRX-616a drug candidates, reporting positive operating cash flow for the quarter ending June 2025.

ECP Emerging Growth Limited reports steady financial health for its convertible notes, confirming a stable loan-to-value ratio and full compliance with regulatory requirements for Q2 2025.

ikeGPS Limited has completed a significant placement of ordinary shares, issuing over 22 million new shares at NZD 0.88 each, representing nearly 14% of its total shares post-issue. The placement prioritized existing shareholders and aims to strengthen the company’s share register.